Megan T. Sniecinski
2020
In 2020, Megan T. Sniecinski earned a total compensation of $2M as Former Chief Business Officer at BioCryst Pharmaceuticals, a 8% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $228,375 |
|---|---|
| Option Awards | $1,271,385 |
| Salary | $456,750 |
| Other | $55,825 |
| Total | $2,012,335 |
Sniecinski received $1.3M in option awards, accounting for 63% of the total pay in 2020.
Sniecinski also received $228.4K in non-equity incentive plan, $456.8K in salary and $55.8K in other compensation.
Rankings
In 2020, Megan T. Sniecinski's compensation ranked 5,478th out of 13,090 executives tracked by ExecPay. In other words, Sniecinski earned more than 58.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,478 out of 13,090 | 58th |
Division Manufacturing | 2,254 out of 5,621 | 60th |
Major group Chemicals And Allied Products | 898 out of 2,254 | 60th |
Industry group Drugs | 775 out of 1,954 | 60th |
Industry Biological Products, Except Diagnostic Substances | 185 out of 411 | 55th |
Source: SEC filing on April 25, 2022.
Sniecinski's colleagues
We found four more compensation records of executives who worked with Megan T. Sniecinski at BioCryst Pharmaceuticals in 2020.